Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 6/20 | 0.37 |
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803348 | 1.00 | DRD3 (0.37) | DRD3DRD2PDE4DALDH1A1ALOX5 | |
| SCHEMBL802974 | 1.00 | DRD3 (0.37) | DRD3DRD2PDE4DALDH1A1ALOX5 | |
| SCHEMBL802970 | 0.91 | ALDH1A1 (0.39) | PDE4DALDH1A1ALOX5HDAC6ACHE | |
| SCHEMBL803415 | 0.90 | ALDH1A1 (0.38) | DRD3DRD2PDE4DALDH1A1ALOX5 | |
| SCHEMBL803409 | 0.88 | ALOX5 (0.36) | PDE4DALDH1A1ALOX5HTR2AHTR2C | |
| SCHEMBL802978 | 0.88 | ALOX5 (0.36) | PDE4DALDH1A1ALOX5HTR2AHTR2C | |
| SCHEMBL803351 | 0.88 | ALOX5 (0.36) | PDE4DALDH1A1ALOX5HTR2AHTR2C | |
| SCHEMBL802967 | 0.79 | ALDH1A1 (0.39) | PDE4DALDH1A1ALOX5HDAC6 | |
| SCHEMBL802973 | 0.78 | ALDH1A1 (0.38) | PDE4DALDH1A1ALOX5HDAC6 | |
| SCHEMBL803352 | 0.75 | TSHR (0.40) | PDE4DALDH1A1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | DRD3 85/4885DRD2 64/4885PDE4D 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.